CTKB — Cytek Biosciences, Inc. stock price, charts and financials

QT44Cytek Biosciences, Inc.

Cytek Biosciences, Inc. (NASDAQ: CTKB) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
4.66
+0.46+10.95%
CTKBQT44Cytek Biosciences, Inc.·NASDAQ
4.66+10.95%
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
Index-P/E-EPS (ttm)-0.58Insider Own9.93%Shs Outstand129.14MPerf Week-0.47%
Market Cap542.40MForward P/E-EPS next Y-0.26Insider Trans0.00%Shs Float118.26MPerf Month-8.50%
Enterprise Value495.01MPEG0.05EPS next Q-Inst Own-Short Float4.25%Perf Quarter-14.63%
Income-80.38MP/S2.62EPS this Y41.95%Inst Trans-Short Ratio3.69Perf Half Y-6.67%
Sales206.71MP/B1.69EPS next Y22.77%ROA-18.03%Short Interest5.03MPerf YTD-16.83%
Book/sh-P/C-EPS next 5Y-ROE-23.53%52W High6.86 -32.04%Perf Year7.97%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-11.90%52W Low3.64 28.05%Perf 3Y-52.97%
Dividend Est.-EV/EBITDA-Sales past 3/5Y7.02% 16.67%Gross Margin53.23%Volatility4.83% 4.03%Perf 5Y-81.06%
Dividend TTM-EV/Sales2.39EPS Y/Y TTM-1158.13%Oper. Margin-21.60%ATR (14)0.19Perf 10Y-
Dividend Ex-Date-Quick Ratio3.86Sales Y/Y TTM2.00%Profit Margin-38.98%RSI (14)41.10Recom2.60
Dividend Gr. 3/5Y-Current Ratio4.48EPS Q/Q-33.33%SMA20-5.26%Beta1.15Target Price5.13
Payout0.00%Debt/Eq0.08Sales Q/Q7.32%SMA50-2.65%Rel Volume0.44Prev Close4.20
Employees700LT Debt/Eq0.04EarningsNov 04SMA200-8.26%Avg Volume1.40MPrice4.66
IPO DateJul 23, 2021Option/ShortYes / YesEPS/Sales Surpr.-29.73% -0.22%Net Debt/EBITDA1.57Volume616,073Change10.95%
Analyst Ratings
DateActionAnalystRatingTarget
May-13-26ReiteratedStephens & Co.Overweight$4.75
May-12-26ReiteratedMorgan StanleyEqual Weight$6.00$5.50
Dec-01-25ReiteratedMorgan StanleyEqual Weight$6.00
Mar-04-25ReiteratedPiper SandlerOverweight$8.50$8.00
Feb-02-25ReiteratedGoldman SachsBuy$4.50$5.25
May-13-24ReiteratedPiper SandlerOverweight$16$8.50
Latest News
Aug-06-26
Aug-05-26
Aug-05-2608:04PM
Jul-29-26
Jul-23-26
Jul-22-26
Jul-20-26
Jul-15-26
Jun-15-26
Company

Cytek Biosciences, Inc. is a company dedicated to cell analysis solutions, offering advanced tools that facilitate scientific progress in both biomedical research and clinical settings. Their primary offerings include the Aurora and Northern Lights spectrum flow cytometers. These instruments conduct comprehensive cell analysis by leveraging fluorescence signatures from multiple lasers to differentiate between various fluorescent tags on individual cells. Complementing these, the Aurora Cell Sorter system utilizes full spectrum profiling technology to broaden the range of potential applications in cell analysis. Beyond instrumentation, Cytek provides essential reagents and kits. These include cFluor reagents, which are antibodies conjugated with fluorochromes, specifically designed to identify target cells for analysis on their systems. They also offer a 25-color immunoprofiling assay, a ready-to-use solution for pinpointing major human immune cell subpopulations like TBNK cells, monocytes, dendritic cells, and basophils. To streamline laboratory operations, the company offers automated micro-sampling and sample loader systems. These automated plate loaders are engineered to integrate seamlessly with the Aurora and Northern Lights systems. The intuitive SpectroFlo software accompanies these systems, simplifying the workflow from quality control through to data analysis. Cytek also provides comprehensive customer support resources. Cytek's diverse client base includes pharmaceutical and biopharmaceutical companies, academic research institutions, and clinical research organizations. The company distributes its products through a direct sales force and dedicated support teams in North America, Europe, China, and the Asia-Pacific region. Additionally, it partners with distributors and sales agents to serve markets across European, Latin American, Middle Eastern, and other Asia-Pacific countries. Originally established in 1992 as Cytoville, Inc., the company officially adopted the name Cytek Biosciences, Inc. in August 2015. Its corporate headquarters are situated in Fremont, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
Total Revenue206201200
Cost of Goods Sold Incl. D&A979789
Gross Profit110104111
Selling, General and Administrative Excl. Other11810892
Research and Development383639
Other Operating Expense-111
Operating Income-44-40-21
Interest Expense
100
Unusual Expense
Non-Operating Income (Expense)51115
Net Income Before Taxes-41-30-6
Income Taxes40370
Consolidated Net Income-80-67-6
Net Income From Continuing Operations-80-67-6
Net Income-80-67-6
EPS (Recurring)-0.62-0.52-0.05
EPS (Basic, Before Extraordinaries)-0.62-0.52-0.05
EPS (Diluted)-0.62-0.52-0.05
EBITDA-29-175
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio
Price To Sales Ratio2.923.224.25
Gross Margin53.4051.7455.50
Operating Margin-21.36-19.90-10.50
Net Margin-38.83-33.33-3.00
Shares Outstanding129128131
Market Capitalization601646850
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$6.37$5.30$4.23$3.17$2.10 Close Price0.00K0.00K0.00K0.00K0.00KUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Ball JackDirectorJun 10 '26Option Exercise0.0043,973086,678Jun 12
Imper VeraDirectorJun 10 '26Option Exercise0.0043,973059,679Jun 12
NEFF DEBORAH JDirectorJun 10 '26Option Exercise0.0043,973059,679Jun 12
Holder MichaelDirectorJun 10 '26Option Exercise0.0043,973060,694Jun 12
Holder MichaelDirectorMay 18 '26Option Exercise0.001,454016,721May 20
Chin RichardDirectorMay 18 '26Option Exercise0.006,107022,392May 20
Yan MingCHIEF TECHNOLOGY OFFICERMay 18 '26Option Exercise0.0022,17904,934,944May 20
Busque PhilippeSVP, GLOBAL SALES AND SERVICESMay 18 '26Option Exercise0.0010,464044,890May 20
Jiang WenbinPRESIDENT AND CEOMay 18 '26Option Exercise0.0080,06205,492,212May 20
McCombe William D.Chief Financial OfficerMay 18 '26Option Exercise0.0025,7190115,016May 20
Barnett ValerieCHIEF LEGAL OFFICERMay 18 '26Option Exercise0.0024,2950153,398May 20
Chin RichardDirectorMar 10 '26Option Exercise0.006,107016,285Mar 12
Barnett ValerieCHIEF LEGAL OFFICERMar 10 '26Option Exercise0.0029,7220140,176Mar 12
Busque PhilippeSVP, GLOBAL SALES AND SERVICESMar 10 '26Option Exercise0.009,828037,183Mar 12
Jiang WenbinPRESIDENT AND CEOMar 10 '26Option Exercise0.0083,84405,432,099Mar 12
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.